Goldman Sachs
BLRX

Goldman Sachs’s BioLineRX BLRX Stock Holding History

Goldman Sachs’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-416
Closed -$46K – 6206
2021
Q1 		$46K Buy
+416
New +$50K ﹤0.01% 5947
2020
Q4 		– Sell
-598
Closed -$39K – 5488
2020
Q3 		$39K Sell
598
-349
-37% -$26.4K ﹤0.01% 5205
2020
Q2 		$65K Buy
+947
New +$64.6K ﹤0.01% 5044

Other funds holding BLRX

PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Goldman Sachs's BLRX Position: Q2 2021 in Review

Goldman Sachs sold out of BioLineRX (BLRX) in Q2 2021, closing a stake of 416 shares — an estimated $46K sold.

Goldman Sachs first reported a position in BLRX in Q2 2020 and held it in 3 quarters. The position peaked at $65K in Q2 2020. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2021.

  • Goldman Sachs reported no remaining BioLineRX position as of Q2 2021 after selling out during the quarter.
  • Goldman Sachs sold 416 BioLineRX shares in Q2 2021, an estimated $46K.
  • Goldman Sachs first reported a position in BioLineRX in Q2 2020 and held it in 3 quarters.
  • Goldman Sachs's BioLineRX position peaked at $65K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.